NEW YORK (AP) — Honda is recalling more than 259,000 of its cars across the U.S. due to a problem that can cause the brake pedal to shift out of position, potentially interfering with a driver’s ability to stop or slow down.

According to documents published by the National Highway Traffic Safety Administration, the recall covers certain Honda Pilots between model years 2023 and 2025 — as well cars under the auto maker’s luxury Acura brand: 2021-2025 Acura TLX and 2023-2025 Acura MDX vehicles.

Related Articles

FDA approves the world’s only twice-a-year shot to prevent HIV

Karen Read found not guilty of murder and manslaughter charges, guilty of drunk driving

Amazon hopes to deliver 10,000 robotaxis annually with new factory, challenging Waymo

The assassination of a Chicago mob kingpin 50 years ago remains unsolved

Trial in Idaho college student killings could face a new delay

The NHTSA’s recall report notes that the brake pedal pivot pin in some of these vehicles was not secured properly during production. That can lead the pedal to shift out of place and “may lead to unintended application,” the report notes, increasing crash risks.

“The issue could also cause an abnormal brake pedal feeling during operation, illuminate the brake malfunction light in the instrument cluster, or cause the vehicle’s brake lights to remain lit even when the brake pedal is not applied,” America Honda said in a statement Wednesday.

As a remedy, Honda says authorized dealers will inspect the vehicles covered by this recall and replace the brake pedal assembly if necessary, free of charge. Per the NHTSA’s report, the company estimates 1% of these vehicles have this issue.

Dealer notifications began on June 13. And mailed owner notification letters are set to follow on July 28. In the meantime, drivers can also confirm if their specific vehicle is included in this recall and find more information using the NHTSA site or Honda’s recall lookup.

Between February 2024 and June 5, the NHSTA notes, Honda received three warranty claims related to this issue — but no reports of injuries.

Honda began investigating the faulty brake pedal in April 2024, after receiving a report of a vehicle experiencing this issue. The company later determined that improper assembly of the brake pedal pivot pin occurred at a supplier’s U.S. plant, which has since been closed. Production was transferred to a plant in Mexico — where the supplier now uses a camera sensor “to verify whether the pivot pin is staked,” the recall report notes.

By JOEY CAPPELLETTI, Associated Press

WASHINGTON (AP) — Nearly six months after Joe Biden left the White House, Senate Republicans are still scrutinizing his presidency, kicking off the first in what’s expected to be a series of congressional hearings this year on his mental fitness in office.

Republicans on the Senate Judiciary Committee brought in three witnesses Wednesday — none of whom served in Biden’s administration — to scrutinize his time in office, arguing that Biden, his staff and the media must be held accountable. Democrats boycotted the hearing and criticized Republicans for “arm chair diagnosing” Biden when the committee could be looking into serious matters.

Sen. John Cornyn of Texas, who co-chaired the hearing, said that they will aim to “shine a light on exactly what went on in the White House during Biden’s presidency.”

“We simply cannot ignore what transpired because President Biden is no longer in office,” Cornyn said.

A spokesperson for Biden declined to comment on the hearing.

Sen. Katie Britt, R-Ala., questions the witnesses during a Senate Committee on the Judiciary hearing oon Capitol Hill, Wednesday, June 18, 2025, in Washington. (AP Photo/Rod Lamkey, Jr.)

It was the first in what could be several hearings about Biden in the coming months. Over in the House, the Oversight Committee has subpoenaed several of Biden’s former staff members, along with his White House doctor, ordering him to testify at a June 27 hearing “as part of the investigation into the cover-up of President Joe Biden’s cognitive decline.”

Questions about Biden’s age and fitness erupted last summer after his disastrous performance in a debate against Donald Trump, which ultimately led to his withdrawal from the race.

Even after Trump won back the presidency in November, Republicans have continued to hammer on Biden’s age, citing in part new reporting about Biden that was published this year.

Related Articles

New CDC advisers will skip some expected topics and explore a target of antivaccine activists

As Israel strikes Iran, many wonder if the US will deepen its involvement

What to know about the impacts of the Supreme Court’s ruling on transgender care for youth

Federal judge to deny Trump administration’s motion to dismiss lawsuit over block on wind projects

Trump’s plan to kill dozens of NASA missions threatens US space supremacy

Trump now alleges that Biden administration officials may have forged the former president’s signature and taken sweeping actions without his knowledge, though he provided no evidence of that happening. But Trump has ordered lawyers at the White House and the Justice Department to investigate.

Republicans played clips during the hearing Wednesday of Democrats defending Biden. In the montage, the Democrats talk about how Biden was mentally sharp when he was in office.

“Most Democrats on this committee have chosen to all but boycott the hearing and have failed to call a single witness,” said Sen. Eric Schmitt, R-Mo. “They have chosen to ignore this issue, like they ignored President Biden’s decline.”

Sen. Dick Durbin, the committee’s top Democrat, criticized Republicans for holding a hearing on the last president at a time when “numerous critical challenges facing the nation that are under our jurisdiction.”

“Apparently arm chair diagnosing former President Biden is more important than the issues of grave concern,” said Durbin of Illinois.

After his opening remarks, Durbin played a video montage of his own — but with clips of Trump speaking that he said reflected the “cognitive ability” of the current president. Durbin left the hearing after his opening remarks.

Three witnesses testified: former White House Press Secretary Sean Spicer, former White House official Theodore Wold and University of Virginia law professor John Harrison. Spicer and Wold both served under Trump.

Sean Spicer, former White House press secretary, host of The Sean Spicer Show, arrives to testify at a Senate Committee on the Judiciary hearing oon Capitol Hill, Wednesday, June 18, 2025, in Washington. (AP Photo/Rod Lamkey, Jr.)

Much of the focus was on Biden’s alleged use of an autopen. Trump has repeated long-standing allegations that the Biden White House relied on an autopen to sign presidential pardons, executive orders and other key documents, claiming that its use cast doubt on their validity.

GOP Sen. Katie Britt also questioned Spicer on “what mechanisms should we put in place” to hold the media accountable “for not actually following what is clearly in front of them.”

By LAURAN NEERGAARD, Associated Press

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It’s the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option.

While a vaccine to prevent HIV still is needed, some experts say the shot — a drug called lenacapvir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take.

“This really has the possibility of ending HIV transmission,” said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research.

Condoms help guard against HIV infection if used properly but what’s called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir’s six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills.

But upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects.

Related Articles

Older adults in the US are increasingly dying from unintentional falls

As cannabis users age, health risks appear to grow

What to know about the COVID variant that may cause ‘razor blade’ sore throats

Deadly listeria outbreak linked to chicken alfredo fettucine sold at Kroger and Walmart

Purdue Pharma’s $7B opioid settlement could advance after states back it

Millett said “gaping holes in the system” in the U.S. and globally “are going to make it difficult for us to make sure we not only get lenacapavir into people’s bodies but make sure they come back” even as little as twice a year.

Gilead’s drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. It’s given as two injections under the skin of the abdomen, leaving a small “depot” of medication to slowly absorb into the body.

Gilead didn’t immediately announce its price. The drug only prevents HIV transmission – it doesn’t block other sexually transmitted diseases.

Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide.

Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere.

About half of new infections are in women, who often need protection they can use without a partner’s knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners.

A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV.

Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up.

“Now I forget that I’m on PrEP because I don’t have to carry around a pill bottle,” said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities.

“Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,” he added. Just remembering a clinic visit every six months “is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you’re taking your pill every day.”

“Everyone in every country who’s at risk of HIV needs access to PrEP,” added Dr. Gordon Crofoot of Houston, who helped lead the study in men. “We need to get easier access to PrEP that’s highly effective like this is.”

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

It’s Kevin Durant.

That’s the thought in many minds when trade winds circulate regarding one of the better scorers to ever touch a basketball.

Few have put the ball in the bucket with the volume and efficiency at which “KD” has done it. Even at 36 (he’ll be 37 when the 2025-26 campaign tips off), Durant averaged 26.2 points per game last year with elite shooting efficiency.

How do you not trade for that guy if the opportunity presents itself? Especially Minnesota, which is searching for ways to take that next step after reaching the Western Conference Finals in consecutive seasons.

But it’s not that simple, and not just because Durant reportedly isn’t all that interested in playing in Minnesota — the reality is he doesn’t have final say on that, though the Wolves probably wouldn’t want to bring in an already disgruntled player.

But also because this is not prime Kevin Durant. While he’s still a supreme shooter, he doesn’t put pressure on the rim – Durant took just two shots per game in the restricted area this past season (for reference: Naz Reid averaged 2.8, and Nickeil Alexander-Walker and Donte DiVincenzo were both at 1.5) – and his defensive impact has waned over the past two seasons.

Whether the latter is due to age or Phoenix’s team-wide defensive ineptitude remains to be seen.

It’s quite possible Durant could seamlessly slip into Minnesota’s roster and perfectly handle the defensive assignments given to him on a team where talent on that end of the floor is abundant. And offensively, as Oklahoma City has demonstrated in these playoffs, it sure is beneficial to have someone who can consistently get and bury a contested 16-foot jumper when the going gets tough. Durant is also an excellent floor spacing option.

Does he fit Minnesota’s roster? Yes. For that reason, such an acquisition makes a lot of sense for the Timberwolves. But only if the roster he would come into post-trade still resembles today’s.

Rudy Gobert is a logical salary to go the other way to Phoenix in a Durant trade. He also would fill the Suns’ gaping hole at center. But doesn’t Durant fit best on a Wolves roster that still has Gobert? One with a defensive anchor who’s steadied the ship for a few years now in Minnesota and creates a high regular-season floor?

Durant was just part of a team missing a legitimate center option in Phoenix. That didn’t go great. Ideally, he’s entering a situation where he contributes but isn’t overly leaned upon for rebounding and defense.

And Durant would alleviate Minnesota’s spacing concerns. But those largely exist with Gobert in the fold. A Durant-Gobert frontcourt feels like a good complement to one another. Swapping out Gobert for Durant may swing Minnesota’s pendulum too far the other direction.

More versatile, but also far more volatile?

Perhaps you could live with that if you’re Tim Connelly and Co. The regular season could be more complicated in a post-Gobert world, but if you could still chart a course back to the conference finals, Durant could help you break through that ceiling that the current roster with Gobert has hit on multiple occasions.

But if such a trade also features Donte DiVincenzo, the No. 17 pick in this year’s draft and Terrence Shannon Jr., now your wing depth is depleted to the point where re-signing Nickeil Alexander-Walker becomes a must, with no guarantee that it will be feasible to do so. Otherwise you’re staring down a reserve backcourt of Rob Dillingham and Jaylen Clark behind an aging Mike Conley. That’s an even scarier proposition without the great stabilizer – Gobert – there to cover up holes.

Minnesota’s depth would be strained, as would the cupboard of assets it could use to address any potential weak points on the roster.

Trading for Durant would be a clear championship-level swing. And believing Durant could help them reach such a goal is the only reason the Timberwolves would make such a move. The Wolves clearly believe they’re close.

Would they be closer after such an acquisition?

That depends on the cost.

Related Articles

NBA Finals: Keys to victory, players to watch, TV information

Tim Connelly wants continuity for the Timberwolves … probably

The next step for Timberwolves’ title pursuit? More attention to detail

Was this a bite at the apple? The numbers, and the West finals, say Wolves weren’t title contenders

Naz Reid intends to re-sign with the Timberwolves, but wants to do more